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CAPSULE 
Background: The roles of different PMCA 
isoforms are not fully understood particularly in 
cell death. 
Results: PMCA4 and PMCA1 silencing has 
differential effects on Ca2+ signaling and caspase-
dependent and independent cell death in MDA-
MB-231 cells. 
Conclusion: PMCA isoforms have distinct roles in 
the control of cell death pathways. 
Significance: Inhibition of PMCA4 may increase 
the effectiveness of some cancer therapies.  
 
SUMMARY 
Plasma Membrane Calcium ATPases 
(PMCAs) actively extrude Ca2+ from the cell 
and are essential components in maintaining 
intracellular Ca2+ homeostasis. There are four 
PMCA isoforms (PMCA 1-4) and alternative 
splicing of the PMCA genes creates a suite of 
calcium efflux pumps. The role of these 
different PMCA isoforms in the control of 
calcium-regulated cell death pathways and the 
significance of the expression of multiple 
isoforms of PMCA in the same cell type are not 
well understood. In these studies we assessed 
the impact of PMCA1 and PMCA4 silencing on 
cytoplasmic free Ca2+ signals and cell viability 
in MDA-MB-231 breast cancer cells. The 
PMCA1 isoform was the predominant regulator 
of global Ca2+ signals in MDA-MB-231 cells. 
PMCA4 played only a minor role in the 
regulation of bulk cytosolic Ca2+, which was 
more evident at higher Ca2+ loads. Although 
PMCA1 or PMCA4 knockdown alone had no 
effect on MDA-MB-231 cell viability, silencing 
of these isoforms had distinct consequences on 
caspase-independent (ionomycin) and 
dependent (ABT-263) cell death. PMCA1 
knockdown augmented necrosis mediated by 
the Ca2+ ionophore ionomycin, whereas 
apoptosis mediated by the Bcl-2 inhibitor ABT-
263 was enhanced by PMCA4 silencing. 
PMCA4 silencing was also associated with an 
inhibition of NFκB nuclear translocation and a 
NFκB inhibitor phenocopied the effects of 
PMCA4 silencing in promoting ABT-263 
induced cell death. This study demonstrates 
distinct roles for PMCA1 and PMCA4 in the 
regulation of calcium signaling and cell death 
pathways despite the widespread distribution of 
these two isoforms. The targeting of some 
PMCA isoforms may enhance the effectiveness 
of therapies that act through the promotion of 
cell death pathways in cancer cells. 
 
Plasma membrane calcium (Ca2+)1 ATPases 
(PMCAs) actively remove cytoplasmic free Ca2+ 
([Ca2+]CYT) and are essential regulators of basal 
Ca2+ (1). PMCAs also contribute to the duration 
and amplitude of Ca2+ transients evoked by many 
physiological stimuli (1,2), and participate in the 
decoding of the Ca2+ signal into a multitude of 
cellular processes (3). 
Separate genes encode for each of the four 
PMCA isoforms (PMCA1-4), with alternative 
splicing of PMCA transcripts acting to further 
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enhance their biological diversity (1,4). The 
identification of more than thirty PMCA variants 
(4) and studies in mice null for specific PMCA 
isoforms support distinct roles for specific PMCA 
isoforms. For example, PMCA2 null mice have 
hearing and balance disorders (5) and produce milk 
with reduced Ca2+ levels (6). Differences in the 
consequences of PMCA knockdown are apparent 
even between PMCA isoforms with almost 
ubiquitous tissue distribution such as PMCA1 and 
PMCA4. PMCA1 knockout is embryonically lethal 
in mice (5) whereas PMCA4 knockout mice, 
although associated with male infertility are 
generally healthy  (5,7,8). 
Studies have started to identify some of the 
potential mechanisms that may underpin the 
functions predicted for specific PMCA isoforms. 
One such example is the differential association of 
PMCA1, PMCA2 and PMCA4 with calcineurin in 
MCF-7 cells (9). The functional significance of 
this interaction has not been investigated in MCF-7 
cells, however, in cardiac cells PMCA4 regulates 
nuclear factor of activated T-cells (NFAT), a 
calcineurin regulated transcription factor, and 
cardiac hypertrophy (10). 
One process where the relative contribution of 
specific PMCA isoforms may be particularly 
important, but has not been fully addressed is cell 
death, where the duration and amplitude of 
increases in [Ca2+]CYT are critical (11,12). Initiators 
of cell death include Ca2+ ionophores that produce 
sustained (µM) increases in [Ca2+]CYT that can 
induce necrotic cell death (13) and inhibitors of B-
cell lymphoma-2 protein (Bcl-2) (14-16). Bcl-2 
inhibitors promote apoptosis by blocking the pro-
survival activity of Bcl-2 proteins (14-16) and are 
undergoing clinical trial assessment for the 
treatment of specific types of lymphomas and solid 
lung cancers (17).  
A few studies have assessed the consequences 
of PMCA expression on cell death. In HeLa cells, 
PMCA overexpression protects from ceramide-
induced cell death (18).  The authors attributed this 
to alterations in intracellular Ca2+ stores, given that 
PMCA overexpression in CHO cells reduces Ca2+ 
levels within the endoplasmic reticulum and 
mitochondria (19). In the context of breast cancer, 
where cells acquire the ability to evade cell death 
(20), assessment of PMCA has been restricted to 
overexpression studies in T47D breast cancer cells 
(21). Recombinant PMCA2 expression attenuates 
increases in [Ca2+]CYT associated with ionomycin-
induced cell death (21).   
Although PMCA2 knockdown has been 
assessed in spinal cord neurons (22) and SH-SY5Y 
neuroblastoma cells (23), and PMCA4 knockdown 
evaluated in HT-29 colon cancer cells (24), 
isoform-specific PMCA knockdown has not yet 
been studied in breast cancer cells. In addition, the 
differential role of PMCA isoforms in the 
regulation of distinct cell death mechanisms, 
within the same cell type has not been evaluated. 
In the present study we compared siRNA-mediated 
knockdown effects of PMCA1 and PMCA4 in the 
regulation of global Ca2+ signals and assessed the 
effects on the viability of MDA-MB-231 breast 
cancer cells, in the absence and presence of the cell 
death initiators, ionomycin (Ca2+ ionophore) and 
ABT-263 (Bcl-2 inhibitor). 
EXPERIMENTAL PROCEEDURES 
Cell culture―The human breast cancer cell 
line MDA-MB-231 (American Type Culture 
Collection) was cultured in high glucose DMEM 
(Sigma Aldrich) supplemented with 10% FBS and 
4 mM L-glutamine (Gibco) at 37°C/5% CO2 in a 
humidified air incubator. All cultures were 
periodically screened for mycoplasma infection. 
siRNA-mediated knockdown of PMCA4 and 
PMCA1 gene expression― MDA-MB-231 cells 
were seeded into 96-well plates and allowed to 
adhere overnight. DharmaFECT 4 (0.1-0.2 
µL/well, Dharmacon) was used to transfect cells 
with Dharmacon ON-TARGETplusTM 
SMARTpool siRNA, which consists of four-
pooled siRNA sequences rationally designed to 
minimize off target effects (25,26). The siRNAs 
used in this study included those for PMCA4 
(siPMCA4, L-006118-00), PMCA1 (siPMCA1, L-
006115-00) and the non-targeting control siRNA 
(siNT, D-001810-10). All experiments had mRNA 
knockdown >70% at 24 h or 48 h post-siRNA. 
Real Time RT-PCR―Cells were plated at 
5.0×103 cells per well into 96-well plates and 
siRNA-transfected. Total RNA was isolated 
(RNeasy Plus Mini Kit; Qiagen) 24 h or 48 h post-
transfection and then reverse transcribed using the 
Omniscript RT kit (Qiagen) according to the 
manufacturer’s protocol. Target cDNA were 
amplified using the TaqMan Fast Universal PCR 
Master Mix (Applied Biosystems) and TaqMan 
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Gene Expression assays (PMCA4, 
Hs00608066_m1; PMCA1, Hs00155949_m1) and 
standard cycling conditions with a StepOnePlus 
Real Time PCR system (Applied Biosystems). 
PMCA4 and PMCA1 mRNA levels were 
quantified by the comparative Ct method as 
previously described (27), normalizing to 18S 
rRNA (4319413E) and presented relative to the 
siNT control. 
Cytoplasmic free Ca2+ measurements― 
MDA-MB-231 cells were plated at 7.5×103 cells 
per well into 96-well plates and siRNA-
transfected. Transfection media was removed 72 h 
post-siRNA treatment and cells were loaded with 
culture medium containing Fluo-4 AM (4 µM; 
Molecular Probes) or Fluo-4FF AM (4 µM; 
Molecular Probes) and incubated at 37°C for 30 
min in a 5% CO2 humidified air incubator. Loading 
solution was replaced with physiological salt 
solution (PSS; 5.9 mM KCl, 1.4 mM MgCl2, 10 
mM HEPES, 1.2 mM NaH2PO4, 5 mM NaHCO3, 
140 mM NaCl, 11.5 mM Glucose, 1.8 mM CaCl2), 
cells were equilibrated to room temperature and 
then washed twice with PSS containing bovine 
serum albumin (BSA, 0.3%). [Ca2+]CYT was 
measured using a FLIPRTETRA (Molecular Devices 
Corporation) and fluorescence was recorded using 
an excitation intensity of 470-495 nm and a 515-
575 nm emission filter. Fluorescence was 
normalized to baseline values to assess relative 
[Ca2+]CYT.   
Immunoblotting―Cells were plated at 5.0×103 
cells per well into 96-well plates and siRNA-
transfected. Cell extracts were harvested 72 h post-
transfection in protein lysis buffer supplemented 
with protease inhibitor cocktail (Roche Applied 
Science) as previously described (24). Proteins 
were separated using gel electrophoresis and 
transferred onto a polyvinylidene fluoride 
membrane as previously described (28). 
Membranes were probed with monoclonal anti-
PMCA4 antibody (1:1000, JA9, Pierce 
Antibodies), monoclonal anti-PMCA antibody 
(1:2000, 5F10, Pierce Antibodies) and monoclonal 
anti-β-actin antibody (1:10,000, Sigma Aldrich). 
Anti-mouse horseradish peroxidase-conjugated 
secondary antibody (1:10000, BioRad) was used to 
visualise protein bands by chemiluminescence 
using Super-Signal West Dura (Pierce). All 
antibodies were diluted in PBST (0.1% Tween-20 
in PBS) with skim milk powder (2.5%). Images 
were acquired and analyzed by densitometry using 
a VersaDoc instrument and Quantity One Analysis 
software (Bio-Rad), respectively. All data were 
normalized to the β-actin loading control and are 
presented relative to siNT. 
Assessment of cell viability―MDA-MB-231 
cells were plated at 5.0×103 cells per well into 96-
well plates and siRNA-transfected. At 72 h post-
transfection media was removed and cells were 
treated with ABT-263 (Selleckchem), ionomycin 
(Enzo Life Sciences), Z-VAD-FMK (Enzo Life 
Sciences), IMD-0354 (Sigma-Aldrich) or DMSO 
(up to 1%) for 48 h in phenol-red free DMEM 
containing FBS (8%). Live cells were stained at 
37°C for 15 min with Hoechst 33342 (10 µg/mL, 
Invitrogen) and propidium iodide (1 µg/mL, 
Invitrogen). Images were acquired using an 
ImageXpress micro automated epifluorescence 
microscope (Molecular Devices Corporation) with 
a 10X objective.  
Assessment of NFκB nuclear translocation― 
MDA-MB-231 cells were plated at 3.5×103 cells 
per well into 96-well plates and transfected with 
siRNA. Post-siRNA transfection (48 h), media was 
removed and cells were deprived of serum (2% 
FBS) for 12 h, prior to the addition of phorbol 12-
myristate 13-acetate  (PMA, 50nM, Sigma) or 
DMSO (0.05%) for 1 h in DMEM (10% FBS). 
Cells were fixed (4% paraformaldehyde in PBS), 
blocked (PBS, 5% normal goat serum and 0.3% 
Triton X-100) and then stained with the polyclonal 
anti-NFκB p65 antibody (Cell Signaling 
Technologies) diluted 1:100 in PBS containing 
BSA (1%) and Triton X-100 (0.3%). NFkB was 
visualized using anti-rabbit IgG (H+L), F(ab')2 
Fragment Alexa Fluor® 555 Conjugate Secondary 
antibody (1:500, Cell Signaling Technologies). 
Cell nuclei were stained with DAPI (40 nM, 
Invitrogen) and images acquired using an 
ImageXpress micro automated epifluorescence 
microscope (Molecular Devices Corporation) with 
a 10X objective. NFκB translocation was assessed 
using the translocation package. 
Statistical Analysis―All statistical tests were 
performed as described in the figure legends using 
GraphPad Prism version 5.04 for Windows. 
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RESULTS 
siRNA-mediated knockdown of specific 
PMCA isoforms in MDA-MB-231 breast cancer 
cells― There was a significant (P < 0.05) 
reduction in PMCA4 (Fig. 1A) and PMCA1 (Fig. 
1B) mRNA levels in cells transfected with PMCA4 
siRNA or PMCA1 siRNA, respectively, compared 
to the siNT control. PMCA4 protein expression 
was also significantly (P < 0.05) reduced by 
PMCA4 siRNA (Fig. 1C, D), but was not 
associated with significant changes in total PMCA 
protein expression (Fig. 1C, E). Consistent with 
high levels of PMCA1, total PMCA protein levels 
were reduced by PMCA1 siRNA (Fig. 1C, E; P < 
0.05). This was not associated with changes in 
PMCA4 expression (Fig. 1C, D).  
Consequences of PMCA1 and PMCA4 
knockdown on [Ca2+]CYT in MDA-MB-231 breast 
cancer cells― In the absence of extracellular Ca2+, 
increases in [Ca2+]CYT elicited by the sarcoplasmic-
endoplasmic reticulum Ca2+-ATPase inhibitor 
cyclopiazonic acid (CPA, 10 µM) were markedly 
altered with siRNA-mediated knockdown of 
PMCA1, but not by PMCA4 knockdown (Fig. 2A-
D). PMCA1 silencing significantly (P < 0.05) 
delayed the time to reach the maximal Ca2+ 
response (Fig. 2B), increased the half-peak decay 
time (Fig. 2C) and increased the area under the 
curve (Fig. 2D) compared to siNT. The effect was 
isoform-specific, as PMCA4 knockdown did not 
alter the nature of the CPA-induced Ca2+ response 
when compared with siNT (Fig. 2A-D).  
The purinergic receptor agonist ATP (100 µM) 
induced a rapid rise in [Ca2+]CYT (Fig. 2E), with no 
significant difference in the peak maximum 
between siRNA treatments (mean ± SD;  
siPMCA1, 2.56 ± 0.23; siPMCA4, 2.68 ± 0.31; 
siNT, 2.99 ± 0.39). However, PMCA1 knockdown 
significantly altered the recovery of [Ca2+]CYT after 
ATP  stimulation (Fig. 2F-H) in comparison to 
siNT, resulting in a slower rate of [Ca2+]CYT decay 
in the absence of extracellular Ca2+ (Fig. 2F), a 
delay in half peak decay time (Fig. 2G) and an 
increase in the area under the curve  (Fig. 2H). 
These effects were isoform-specific as similar 
changes were not seen with PMCA4 silencing 
(Fig. 2E-H).  
To assess the consequences of isoform-specific 
PMCA knockdown with [Ca2+]CYT increases of a 
greater magnitude, we compared the effects of 
PMCA4 and PMCA1 siRNA on [Ca2+]CYT changes 
mediated by the Ca2+ ionophore ionomycin in the 
presence of extracellular Ca2+ (1.8 mM).  
Increases in [Ca2+]CYT mediated by ionomycin 
(3 µM) were significantly (P < 0.05) increased 
with PMCA1 and PMCA4 knockdown compared 
to siNT (Fig. 3A, B).  These effects were more 
pronounced (P < 0.05) with PMCA1 knockdown 
compared to PMCA4 knockdown (Fig. 3A, B). 
Silencing of PMCA1 and PMCA4 also augmented 
increases in [Ca2+]CYT mediated by 10 µM 
ionomycin, however, in contrast to 3 µM 
ionomycin there were no differences in effect 
between the two isoforms (Fig. 3C, D).  
Assessment of PMCA1 and PMCA4 
knockdown on cell viability in MDA-MB-231 
breast cancer cells― No effect on cell viability 
was detected with knockdown of PMCA4 (Fig. 4A, 
B, D) or PMCA1 (Fig. 4A, C, D) compared to 
siNT. Reduced Ca2+-efflux mediated by either 
PMCA1 or PMCA4 silencing was therefore 
insufficient for the activation of cell death 
pathways in MDA-MB-231 cells. 
Mechanism of ionomycin and ABT-263 
activated cell death in MDA-MB-231 cells―To 
assess whether reduced PMCA1 or PMCA4 
expression could alter the responsiveness of breast 
cancer cells to different cell death mechanisms, we 
first characterized cell death in MDA-MB-231 
cells initiated by the Ca2+ ionophore ionomycin 
(Fig 5A, C) and the Bcl-2 inhibitor, ABT-263 (Fig 
5A, E). Ionomycin (10 µM) and ABT-263 (10 µM) 
both initiated significant (P < 0.05) increases in 
cell death compared to control (Fig. 5G, H). The 
nature of the initiated cell death was probed using 
the pan-caspase inhibitor, Z-VAD-FMK (50 µM). 
Consistent with a necrotic mechanism (13) 
ionomycin (10 µM)-induced cell death was not 
affected by Z-VAD-FMK (Fig. 5C, D, G) whereas 
cell death initiated by ABT-263 was almost 
entirely prevented by caspase inhibition (Fig. 5E, 
F, H) indicating an apoptotic pathway (29).  
Consequences of PMCA1 and PMCA4 on 
ionomycin-induced necrosis in MDA-MB-231 
breast cancer cells―Necrosis mediated by 
submaximal ionomycin (3 µM) was not 
significantly affected by PMCA4 knockdown (Fig. 
6A, B, G), however, it was significantly (P < 0.05) 
augmented with PMCA1 silencing (Fig. 6A, C, G).  
Additionally, the level of necrosis was 
significantly (P < 0.05) higher in cells treated with 
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PMCA1 siRNA compared to PMCA4 siRNA (Fig. 
6G) at 3 µM.  
For the higher ionomycin concentration (10 
µM) knockdown of both PMCA4 (Fig. 6D, E, G) 
and PMCA1 (Fig. 6D, F, G) significantly (P < 
0.05) elevated the proportion of necrotic cells 
compared to siNT. However, similar to their 
effects on [Ca2+]CYT, the isoform-specific 
differences seen with submaximal ionomycin 
concentration (3 µM) were not detected at higher 
Ca2+ loads associated with 10 µM ionomycin (Fig. 
6G).  
Consequences of PMCA1 and PMCA4 on 
ABT-263-induced apoptosis in MDA-MB-231 
breast cancer cells― Submaximal ABT-263 (3 
µM) induced-apoptosis was significantly  (P < 
0.05) augmented by PMCA4 siRNA compared to 
siNT (Fig. 7A, B, G). This effect was isoform-
specific, as PMCA1 knockdown did not alter 
apoptosis compared to siNT (Fig. 7A, C, G). In 
contrast, ABT-263 (10 µM)-mediated cell death 
was not modulated by either PMCA4 siRNA or 
PMCA1 siRNA compared to siNT (Fig. 7D-G).  
PMCA4 but not PMCA1 knockdown inhibits 
NFκB translocation in MDA-MB-231 breast 
cancer cells― Nuclear factor-κB (NFκB) is a Ca2+ 
dependent transcription factor (30-32), which is 
implicated in breast cancer progression (33) and 
the resistance to cancer therapies (34,35). PMCA4 
is linked to the regulation of Ca2+ dependent 
transcription factors such as NFAT, independent of 
bulk [Ca2+]CYT changes (10). We assessed the 
effects of PMCA4 and PMCA1 silencing on 
nuclear translocation of NFκB induced by PMA 
(50 nM) (36). PMA-induced NFκB nuclear 
translocation (Fig 8A, B) was not affected by 
PMCA1 silencing but was significantly (P < 0.05) 
reduced by PMCA4 siRNA relative to siNT. 
Effects of NFκB inhibition on ABT-263-
induced MDA-MB-231 cell death― To further 
explore the possible link between PMCA4 and 
NFκB on MDA-MB-231 cell death, we assessed 
whether NFκB inhibition could mimic PMCA4 
siRNA by augmenting cell death induced by ABT-
263 (3 µM). The NFκB inhibitor IMD-0354 (10 
µM) (37) did not induce cell death alone  (Fig. 8C-
F), however, it did significantly (P < 0.05) 
augment ABT-263-mediated apoptosis (Fig. 8C-I) 
suggesting that IMD-0354 phenocopies the effect 
of PMCA4 siRNA on ABT-263-mediated cell 
death. 
DISCUSSION 
Despite the proposed differential contributions 
of PMCA isoforms in Ca2+ dependent cellular 
processes few studies have evaluated the specific 
roles of different PMCA isoforms in shaping 
intracellular Ca2+ signals and cellular responses in 
the same cell types. PMCA1 and PMCA4 have a 
broad tissue distribution and frequently co-express 
within the same cell (38). We compared the 
consequences of knockdown of these two PMCA 
isoforms on [Ca2+]CYT signals generated by various 
Ca2+ mobilizing agents. Pronounced effects with 
PMCA1 knockdown but not with PMCA4 
knockdown were seen on the nature of CPA- and 
ATP-induced [Ca2+]CYT transients. PMCA1 siRNA 
reduced the rate of [Ca2+]CYT decay and prolonged 
the ATP Ca2+ response. Previous studies 
overexpressing PMCA isoforms in CHO cells 
found that some variants not only alter Ca2+ 
homeostasis within the cytoplasm but also within 
sub-cellular compartments such as the endoplasmic 
reticulum (2). Agents that increase [Ca2+]CYT by 
inhibition of sarcoplasmic endoplasmic reticulum 
Ca2+-ATPase activity can act as a surrogate marker 
for alterations in endoplasmic reticulum Ca2+ 
levels (39). Hence, PMCA1 knockdown-mediated 
alterations in the CPA-mediated [Ca2+]CYT 
transient, in addition to being a consequence of 
reduced Ca2+ efflux, may also involve increases in 
endoplasmic reticulum Ca2+.      
Our study suggests that in MDA-MB-231 
breast cancer cells, the PMCA1 isoform is the 
major regulator of global [Ca2+]CYT increases, such 
as those generated by IP3-mediated Ca2+ release 
after G-protein coupled receptor activation. The 
significance of PMCA4 in MDA-MB-231 cells 
may become apparent during very high Ca2+ loads.  
Indeed, during the high magnitude increases in 
[Ca2+]CYT initiated by 3 µM ionomycin, a 
contribution for PMCA4 was identified.  However, 
this PMCA4 siRNA-mediated effect was not as 
pronounced as seen with PMCA1 knockdown. 
This finding is also consistent with a predominant 
role for PMCA1 in the regulation of global 
[Ca2+]CYT signals in this cell type and is consistent 
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with previous studies, demonstrating distinct 
phenotypes in PMCA1 and PMCA4 knockout 
animals (5,7,8). PMCA1 ablation is lethal during 
embryogenesis, indicative of its vital role in the 
maintenance of [Ca2+]CYT homeostasis in an array 
of cell types (5). Although PMCA4 has a broad 
tissue distribution, PMCA4 null mice reach 
adulthood and exhibit tissue specific phenotypes 
such as male infertility (5,7,8). These differences 
suggest that PMCA1 adopts a vital housekeeping 
function by regulating global Ca2+ homeostasis and 
supports the involvement of PMCA4 in Ca2+-
dependent signal transduction and cell processes 
by shaping of Ca2+ signals within sub-cellular 
domains (5,7,8).  
We extended our study to examine the 
consequences of PMCA4 and PMCA1 siRNA on 
cell death in the presence of cell death stimuli. 
Initial studies, in the absence of any stimuli, 
showed that the viability of MDA-MB-231 breast 
cancer cells was not affected by PMCA1 or 
PMCA4 knockdown. In contrast, PMCA2 
knockdown produces spinal cord neuronal cell 
death (22,40) in the absence of external stimuli. 
Assessment of PMCA1 and PMCA4 knockdown 
on cell death initiated by ionomycin or ABT-263 
demonstrated distinct roles for PMCA1 and 
PMCA4 in the regulation of caspase-independent 
and dependent cell death pathways, respectively. 
Consistent with the effects seen with ionomycin-
induced [Ca2+]CYT transients, PMCA1 knockdown 
had a more pronounced effect on ionomycin-
induced cellular necrosis than PMCA4 
knockdown. This result further underscores the 
more subtle nature of the change in calcium 
handling in the cell with PMCA4 knockdown. 
Previous results examining PMCA4 as a sensitizer 
of cell death in HT-29 colon cancer cells showed 
that PMCA4 silencing does not alter the sensitivity 
of HT-29 cells to TRAIL or CCCP-induced cell 
death (24). Reduced expression of another PMCA 
isoform, PMCA2, augments ionomycin-mediated 
cell death in SH-SY5Y neuroblastoma cells (23). 
Whereas its overexpression in T47D breast cancer 
cells bestows resistance to ionomycin-mediated 
cell death through the attenuation of [Ca2+]CYT 
responses (21).The potential significance of this 
survival advantage is reflected in the poorer 
prognosis of breast cancer patients with elevated 
expression of PMCA2 (21). Our silencing studies 
suggest that modulators of PMCA isoforms 
involved in global [Ca2+]CYT  may sensitize cells to 
cell death stimuli.  
The Bcl-2 inhibitor (ABT-263) used in this 
study to induce apoptotic cell death in MDA-MB-
231 breast cancer cells is progressing through 
clinical trials (17). A structurally related analogue 
(ABT-737) sensitizes Bcl-2−expressing breast 
cancers to chemotherapies (41), highlighting the 
potential for Bcl-2 inhibitors as a therapeutic 
option for breast cancer. ABT-263-induced cell 
death was not affected by PMCA1 knockdown, but 
instead was augmented upon reduced expression of 
PMCA4. These distinct differences in the 
consequences of isoform-specific PMCA 
knockdown on ionomycin and ABT-263 initiated 
cell death is not totally unexpected, considering 
these agents activate cell death by distinct 
mechanisms and have markedly different effects 
on Ca2+ signals. Ionomycin produces sustained 
global increases in [Ca2+]CYT, augmented by 
PMCA1 siRNA, resulting in Ca2+ overload and cell 
necrosis. Bcl-2 inhibitors such as ABT-263 initiate 
caspase-dependent apoptosis by binding to and 
blocking the pro-survival activity of BH3 domains 
present within Bcl-2 proteins (14-16). Increases in 
intracellular Ca2+ signals, particularly within sub-
cellular compartments, such as the endoplasmic 
reticulum and mitochondria can modulate Bcl-2-
mediated survival pathways (18,42,43). Our 
identification of PMCA4 as a modulator of ABT-
263 mediated cell death may be analogous to the 
characterized role of PMCA4 in cardiac cells, 
where altered PMCA4 expression appears to play 
little role in shaping global [Ca2+]CYT increases 
(10,44) yet is an important regulator of the Ca2+-
dependent transcription factor NFAT influencing 
outcomes such as cardiac hypertrophy (9,10). Ca2+-
dependent gene transcription critically depends on 
localization of Ca2+ signals as well as Ca2+ 
oscillation frequency and amplitude (30,31). Hence 
PMCA4-mediated regulation of transcription may 
be mediated through the fine-tuning of Ca2+ signals 
within localized sub-cellular domains or through 
alterations in oscillation frequency. Context 
dependent modulation of apoptosis by PMCAs is 
reflected in PMCA4 knockout mice studies. 
Smooth muscle cells from the portal veins of 
PMCA4 knockout mice on a mixed 129/SvJ and 
Black Swiss background display features of 
apoptosis during in vitro contraction studies (7). 
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Our study identified PMCA4 siRNA-mediated 
inhibition of NFκB nuclear translocation. 
Pharmacological inhibition of NFκB phenocopied 
the augmentation of ABT-263-mediated apoptosis 
produced by PMCA4 silencing, suggesting that 
PMCA4 siRNA-augmentation of apoptosis may be 
due to modulation of NFκB.  The ability of 
PMCA4 silencing to inhibit NFκB is significant.  
The activity of NFκB is governed by the nature of 
Ca2+ signals (30-32) and Ca2+ influx mediated by 
the calcium channel TRPC1 can inhibit NFκB 
activity in an intestinal epithelial cell line (45). 
Breast cancers with a poor prognosis are associated 
with elevated constitutive activity of NFκB 
(34,35). Agents that inhibit NFκB are themselves 
promising anti-tumour modulators for the 
treatment of breast cancers (46,47) and can 
enhance the effects of Bcl-2 inhibitors (48).  
In summary, we show that PMCA1 is a major 
regulator of global Ca2+ homeostasis in MDA-MB-
231 breast cancer cells and this is associated with 
an ability of PMCA1 silencing to augment necrotic 
cell death generated by high Ca2+ loads. Although, 
PMCA4 is not a key regulator of global changes in 
[Ca2+]CYT associated with many stimuli, our study 
demonstrates a novel relationship between PMCA4 
and NFκB. Our study highlights isoform diversity 
between the two almost ubiquitously expressed 
PMCA isoforms (PMCA1 and PMCA4) and 
identifies PMCA4 as a potential anti-tumor 
modulator. Inhibitors of PMCA4 (49) may be 
novel therapeutics to sensitize some cancer cells to 
apoptotic stimuli. 
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FOOTNOTES 
1Abbreviations: Ca2+, calcium; PMCA, Plasma membrane malcium ATPase; [Ca2+]CYT, cytoplasmic free 
calcium; NFAT, nuclear factor of activated T-cells; Bcl-2, B-cell lymphoma-2; DMEM, Dulbecco’s 
modified Eagle’s medium; FBS, fetal bovine serum; NFκB, nuclear factor-κB, BSA, bovine serum 
albumin; siPMCA1, PMCA1 siRNA; siPMCA4, PMCA4 siRNA; siNT, NT siRNA; cyclopiazonic acid, 
CPA; phorbol 12-myristate 13-acetate,  PMA 
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FIGURE LEGENDS 
 
FIGURE 1. Silencing of PMCA4 and PMCA1 in MDA-MB-231 cells. Quantification of (A) PMCA4 
mRNA and (B) PMCA1 mRNA levels, 48 h post-siRNA transfection with siPMCA4, siPMCA1 or siNT. 
Real time RT-PCR data were pooled from three independent experiments (n=3) performed in triplicate, *P 
< 0.05, one-tailed student’s t-test. (C) Immunoblots of PMCA4 and total PMCA protein expression, 72 h 
post-siRNA transfection. (D) PMCA4 and (E) total PMCA protein expression from densitometic analysis 
normalized to the β-actin loading control, from three independent experiments. *P < 0.05, one-way 
ANOVA, Bonferroni post-hoc analysis. All data shown are mean ± SD. 
 
FIGURE 2. Effect of PMCA1 and PMCA4 silencing on CPA and ATP evoked [Ca2+]CYT increases in 
MDA-MB-231 breast cancer cells. (A) CPA (10 µM)-mediated and (E) ATP (100 µM)-mediated [Ca2+]CYT 
after transfection with siPMCA1, siPMCA4 or siNT in the presence of extracellular BAPTA (100 µM). 
Ca2+ traces represent relative mean fluorescence. (B & F) Time to peak [Ca2+]CYT and rate of [Ca2+]CYT 
decay after CPA and ATP responses, respectively. (C & G) Half peak decay time for CPA and ATP 
responses, respectively. (D & H). Area under the curve for CPA and ATP responses, respectively. Bar 
graphs are mean ± SD for Ca2+ transient parameters. All data were from 3 independent experiments 
performed in triplicate wells  (n=3), *P < 0.05, one-way ANOVA, Bonferroni post-hoc analysis.  
 
FIGURE 3. Ionomycin-evoked [Ca2+]CYT signals in the presence of PMCA1 and PMCA4 silencing. 
MDA-MB-231 breast cancer cells were transfected with siPMCA1, siPMCA4 or siNT and changes in 
[Ca2+]CYT were assessed after the addition of ionomycin (A) 3 µM or (C) 10 µM. Ca2+ traces represent 
relative mean fluorescence. (B & D) Rate of [Ca2+]CYT increase for 3 µM  and 10 µM ionomycin Ca2+ 
responses, respectively. Bar graphs are mean ± SD for Ca2+ transient parameters. All data were from 3 
independent experiments performed in triplicate wells  (n=3), *P < 0.05, one-way ANOVA, Bonferroni 
post-hoc analysis.  
 
FIGURE 4. Cell viability in the presence of siRNA-mediated silencing of PMCA1 and PMCA4 gene 
expression. MDA-MB-231 breast cancer cells were transfected with siPMCA4, siPMCA1 or siNT, 
incubated for a further 48 h and then assessed for cell viability.  Cell viability for (A) siNT, (B) siPMCA4 
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and (C) siPMCA1 presented as dot plots of Hoechst 33342 and propidium iodide fluorescence. Each dot 
plot shows an equal cell number (10,000 cells) randomly selected from three independent experiments 
(n=3) performed in triplicate wells. (D) Bar graph showing the mean ± SD of the proportion of viable cells 
post-siRNA transfection. All data were from 3 independent experiments performed in triplicate wells  
(n=3), *P < 0.05, one-way ANOVA, Bonferroni post-hoc analysis.  
 
FIGURE 5. Effects of the caspase inhibitor Z-VAD-FMK on ionomycin and ABT-263 mediated cell 
death in MDA-MB-231 breast cancer cells. (A-F) Dot plots for control, ionomycin or ABT-263 in either 
in the absence or presence of Z-VAD-FMK. Each dot plot represents an equal number of total cells 
(10,000 cells) selected at random from three independent experiments (n=3) performed in triplicate wells. 
(G & H) The pooled data for the effect of Z-VAD-FMK on the proportion of dead cells induced by 
ionomycin or ABT-263 (mean ± SD). All data were from three independent experiments performed in 
triplicate wells  (n=3), *P < 0.05, repeated measures two-way ANOVA, Bonferroni post-hoc analysis. 
 
FIGURE 6. PMCA1 and PMCA4 silencing effects in promoting ionomycin-mediated cell death in MDA-
MB-231 breast cancer cells. Dot plots of Hoechst 33342 and propidium iodide fluorescence in cells 
transfected with (A, D) siNT, (B, E) siPMCA4, or (C, F) siPMCA1 following treatment with 3 µM or 10 
µM ionomycin. Each dot plot represents an equal number of total cells (10,000 cells) selected at random 
from three independent experiments (n=3), performed in triplicate. (G) The proportion of necrotic cells 
pooled from three independent experiments performed in triplicate wells  (n=3; mean ± SD), *P < 0.05, 
repeated measures two-way ANOVA, Bonferroni post-hoc analysis.  
 
FIGURE 7. PMCA1 and PMCA4 silencing effects in promoting ABT-263-mediated cell death in MDA-
MB-231 breast cancer cells. Dot plots of Hoechst 33342 and propidium iodide florescence in cells 
transfected with (A, D) siNT, (B, E) siPMCA4, or (C, F) siPMCA1 following treatment with ABT-263. 
Each dot plot represents an equal number of total cells (10,000 cells) selected at random from three 
independent experiments (n=3), performed in triplicate. (G) The proportion of apoptotic cells pooled from 
three independent experiments performed in triplicate wells  (n=3; mean ± SD), *P < 0.05, repeated 
measures two-way ANOVA, Bonferroni post-hoc analysis. 
 
FIGURE 8. NFκB activity in the presence of PMCA1 and PMCA4 siRNA and the effect of 
pharmacological inhibition of NFκB on ABT-263-mediated cell death. (A) MDA-MB-231 breast cancer 
cells stained for NFκB (orange) with DAPI (nuclei, blue) and with white arrows depicting translocation of 
NFκB to the nucleus in the (i) absence of PMA (50 nM), (ii) presence of PMA (50 nM), (iii) presence of 
of siPMCA1 and PMA (50 nM) and (iv) presence of siPMCA4 and PMA (50 nM). (B) Percentage of cells 
with NFκB nuclear translocation in siRNA transfected cells following the addition of PMA (50 nM) 
normalized to the DMSO control. (C) The proportion of viable cells following IMD-0354 and/or ABT-263 
treatment. (D) The proportion of apoptotic cells following IMD-0354 and/or ABT-263 treatment. (E-I) 
Dot plots of Hoechst 33342 and propidium iodide fluorescence in cells transfected with siNT or with 
siPMCA4 in the presence of IMD-0354 and/or ABT-263. Each dot plot represents an equal number of 
total cells (10,000 cells) selected at random from three independent experiments. All data were from three 
independent experiments performed in triplicate wells  (n=3) and are presented as mean ± SD where 
relevant, *P < 0.05, repeated measures two-way ANOVA, Bonferroni post-hoc analysis. Scale bar = 25 
µm. 
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